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a b s t r a c t
This review deals with the human adult cardiomyocyte proliferation as a potential source for heart repair
after injury. The mechanism to regain the proliferative capacity of adult cardiomyocytes is a challenge.
However, recent studies are promising in showing that the ‘locked’ cell cycle of adult cardiomyocytes
could be released through modulation of cell cycle checkpoints. In support of this are the signaling
pathways of Notch, Hippo, Wnt, Akt and Jak/Stat that facilitate or inhibit the transition at cell cycle
checkpoints. Cyclins and cyclin dependant kinases (CDKs) facilitate this transition which in turn is
regulated by inhibitory action of pocket protein e.g. p21, p27 and p57. Transcription factors e.g. E2F,
GATA4, TBx20 up regulate Cyclin A, A2, D, E, and CDK4 as promoters of cell cycle and Meis-1 and HIF-1
alpha down regulate cyclin D and E to inhibit the cell cycle. Paracrine factors like Neuregulin-1, IGF-1 and
Oncostatin M and Extracellular Matrix proteins like Agrin have been involved in cardiomyocyte prolif-
eration and dedifferentiation processes.
A molecular switch model is proposed that transforms the post mitotic cell into an actively dividing
cell. This model shows how the cell cycle is regulated through on- and off switch mechanisms through
interaction of transcription factors and signaling pathways with proteins of the cell cycle checkpoints.
Signals triggered by injury may activate the right combination of the various pathways that can ‘switch
on’ the proliferation signals leading to myocardial regeneration.
© 2019 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. Production and
hosting by Elsevier B.V. on behalf of KeAi. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The adult heart has been viewed for decades as a post mitotic
organ with typical characteristics of cardiomyocytes as terminally
differentiated and being incapable of proliferation [1]. This view
was supported by the fact that after birth the development and
growth of the heart switches abruptly from hyperplasia to hyper-
trophy [2,3]. This wouldmean that the cardiomyocytes exhibit non-
proliferative cell cycles that increase the DNA content but without
cell division. The subsequent multinucleation and polyploidization
of cardiomyocytes is seen as the end of replication [4e6]. In addi-
tion, the rigid sarcomeric structure of adult cardiomyocytes makes
them refractory to cytokinesis [7]. Thus, it justiﬁes the notion that
the proliferation of adult cardiomyocytes is ‘locked’. Is it possible
then to ‘unlock’ the adult cardiomyocytes to regenerate the
myocardium that is electrically and mechanically in sync with the
surrounding heart tissue?[8]
Zebra ﬁshmodel is the best studied for demonstrating adult heart
regeneration. Experiments have shown that zebra ﬁsh hearts can
regenerate after apical amputation of the ventricle, cryoinjury, or
genetic ablation [9e11]. This regenerative capacity was also demon-
strated in neonatal mice who recovered from an experimental
myocardial infarction and an apical resection injury within the ﬁrst
day of life [12,13]. The apical defect was replaced by cardiomyocytes
as being identiﬁed by morphology and cardiac troponin T staining.
Cardiomyocytemitosis and cytokinesiswere shownby colocalization
of phosphohistone H3 and aurora B kinase with cardiac troponin T
and sarcomere disassembly. In addition, normal systolic functionwas
observed in the newly formed apex [14]. This remarkable regenera-
tive potential of neonatal mice heart is, however, lost within the ﬁrst
week of life. The exact mechanism for this shift is not known but
coincides with the developmental window when cardiomyocytes
become binucleated and withdraw from the cell cycle [2].
Studies have shown that in humans the cardiomyocyte numbers
increase from 1 to 4 billion from birth to an age of 20 years after
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which the total number of cardiomyocytes remain constant
throughout life [15,16]. The Carbon-14 birth dating method esti-
mated that new cardiomyocytes are generated at a rate of <1% per
year at 25 years decreasing to ~0.45% at 75 years of age, so that about
45% of cardiomyocytes are exchanged during the entire life time of a
person [17]. This regenerative ability, albeit small, might prove to be
important owing to longer life span in humans [18]. It may be suf-
ﬁcient for repairing age related daily wear and tear. However, it is
apparently unable to keep up with cardiomyocyte loss due to heart
failure or to ﬁll in large gaps resulting from myocardial infarction.
Regardless of its effectiveness, it is now established that human
heart is capable of generating new cardiomyocytes after birth [19].
The source of these new cardiomyocytes, however, is still under
debate. Are these new cardiomyocytes coming from differentiation
of resident/homing stem cells in the heart or from division of pre-
existing cardiomyocytes?
Studies both in zebra ﬁsh and mice have demonstrated that it is
the proliferation of preexisting cardiomyocytes and not endoge-
nous progenitor or stem cells that contribute to cardiac regenera-
tion [20e22]. In mice, cell exhibiting speciﬁc cardiac gene markers
were shown to undergo DNA replication and cytokinesis [23]. These
newly regenerated cells demonstrated in turn electromechanical
networking with neighboring myocardium [24]. Latest studies by
He et al [25] and Li et al [26] have provided evidence that the adult
mammalian heart lacks myocyte producing stem cells, so heart
repair cannot be attributed to any progenitor cell and car-
diomyocytes in injured myocardium are derived from preexisting
cardiomyocytes [26,27].
The discovery of endogenous adult cardiomyocytes as a source
of new cardiomyocytes opens a new dimension in the ﬁeld of
regenerative medicine. This may enable the myocardial repair by
stimulating endogenous adult cardiomyocytes proliferation [8].
The possible mechanisms underlying cardiomyocyte prolifera-
tion will be discussed.
2. Cell cycle regulators in heart regeneration
It has been shown that cardiomyocytes withdraw from cell cycle
activity after birth [14]. Post-mitotic, terminally differentiated car-
diomyocytes that results from this transition are associated with
up-regulation of cell cycle inhibitors and down-regulation of cell
cycle promoters at check points G1/S and G2/M through cyclins and
cyclin-dependent kinases (CDKs) [3,15,28,29]. Recent studies are
investigating the mechanisms of how cardiomyocytes exit the cell
cycle to identify ways to re-enter the cell cycle. Mechanism(s) to
regain proliferative capacity of adult cardiomyocytes could be
through modulation of cell cycle checkpoints as is shown in Fig. 1.
Cyclin D is a G1 phase cyclin that drives the G1/S phase transi-
tion. Cell cycle activity in cardiomyocytes expressing cyclin D2
persisted after experimental myocardial infarction in mice with
resulting DNA synthesis and regression of infarct [30]. It means
cyclin D2 is proliferation friendly. Contrastingly, overexpression of
cyclin D1 of adult cardiomyocytes inmice resulted in DNA synthesis
and multinucleation but did not proceed to proliferation [31].
Hence overexpression of cyclin D2 could be a potential target for
stimulating myocardial regeneration after injury.
Fig. 1. Interactions of cell cycle regulators and signaling proteinsmodel for adult cardiomyocyte proliferation. The cell cycle after G0 is time-phased with four phases of G1, S, G2 and
M with the checkpoints at the interphase of G1/S and G2/M. Signaling pathways of Notch, Hippo, Wnt and Akt facilitate or inhibit the transition at checkpoint as shown by the
interacting colored arrows. Cyclins, cyclin dependent kinases (CDKs) facilitate the transition at checkpoints which in turn is regulated by inhibitory action of P21, P27, p28 and P57
on cyclin and CDKs. Akt shows a triple response of inactivating GSK-3b, releasing b-catenin to action, activates cyclin D and inhibits P27 leading to disinhibition of cyclins and CDKs.
Hippo signaling, on one hand activates Yap proteins to regulate b-catenin and on the other hand, it activates insulin like growth factor-1(IGF-1) to switch on Akt signaling. Wnt
signaling activates b-catenin switching on the G1 to S transition. Notch signaling together with Akt inhibits P27 and P57 proteins in order to disinhibit the cyclin-CDK facilitation of
cell cycle checkpoints.
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Cyclin B is a G2 phase cyclin. It drives the cells into and out of M
phase of the cell cycle. It has been shown that the absence of cyclin
B1-CDC2 complex (cell division cycle 2 kinase) mediates G2/M ar-
rest in adult cardiomyocytes. In support of this effect, Bicknell et al
has demonstrated that overexpressing this G2/M regulator protein
stimulated cell division in adult rat cardiomyocytes that had pre-
viously exited the cell cycle [32].
Cyclin Dependent Kinase inhibitors (CKIs) regulate the cyclin-
CDK complexes to control the cell cycle. These thus, can be
manipulated to induce proliferation in cardiomyocytes. P21, p27
and p57 of the CDK interacting protein/kinase inhibitory protein
family of CKIs are present in adult cardiomyocytes to switch off the
cell cycle as shown in Fig. 1. Studies have shown that p27 and p57
work in synergy to control the cell cycle exit and leading to cell
differentiation [33]. P21 controls cell cycle arrest and prevent re-
entry into cell cycle [34]. It has been shown that knockdown of
p21, p27 and p57 genes induced quiescent adult rat cardiomyocytes
to actively proliferate with intact cytokinesis. This phenomenon
was linked to the re-expression of neonatal genes, inhibition of
adult genes and a change in adult cardiomyocyte morphology [35].
Cyclin A2, a key cell cycle regulator mediating G1-S and G2-M
transition, has been shown to increase cardiomyocyte cycling and
cardiac regeneration [36,37]. In rats, delivery of a cyclin A2
expressing adenoviral vector after myocardial infarction improved
cardiac function [37]. It attenuated myocardial ﬁbrosis and caused
an increase in cardiomyocyte number in the infarct zone. Delivery
of the cyclin A2 gene to infarcted porcine hearts also resulted in the
increase in cardiomyocyte mitosis, increase in cardiomyocyte
number, and decrease in ﬁbrosis. Time-lapse microscopy of
cultured porcine cardiomyocytes demonstrated cytokinesis with
preservation of sarcomeric structure [38] showing cyclin A2 as an
important cell cycle regulator in adult cardiomyocytes (Fig. 1).
Cyclins and CKIs, are thus important factors that can be
manipulated to re-enter the cardiomyocyte cell cycle via gene
transfer or pharmacological modulation through small molecules
as will be discussed further.
Recently, it was shown that overexpression of CDK1, CDK4,
cyclin B1, and cyclin D1 efﬁciently induced cell division in post-
mitotic mouse, rat, and human cardiomyocytes [39]. It was also
shown through in vivo lineage tracing experiments that 15e20% of
adult cardiomyocytes expressing these four factors underwent
stable cell division and improved cardiac function after myocardial
infarction. This demonstrates that a speciﬁc combination of genes
could potentially unlock the proliferative ability in those cells that
have exited the cell cycle [39].
3. The signaling pathways controlling cell cycle proteomics to
stimulate adult cardiomyocyte proliferation
PI3K-Akt is an intracellular signaling pathway that is one of the
drivers of cell-cycle as well as promoter of apoptosis. Studies have
shown that constitutive expression of active protein kinase B or Akt
can prolong the half-life of cyclin D, resulting in positive cell-cycle
regulatory effects while inhibition of PI3K speeds up cyclin D1
degradation [40]. The S-phase cyclin-dependent kinase CDK2 is a
target for Akt during cell cycle progression. Expression of p27, a
negative regulator of cell cycle is also decreased by the PI3K-AKT
pathway to facilitate G2/M phase progression [41,42]. Studies in
cardiomyocytes have shown that the number of neonatal as well as
adult cardiomyocytes in the mitotic and cytokinetic phase was
increased after activation of the PI3K-AKT signals [43]. Apart from
its proliferation inducing potential, Akt is also shown to orchestrate
ﬁbroblast-to-cardiomyocyte reprogramming in mice [44].
Wnt/b-catenin signaling is one of the main signaling pathways
to regulate the regenerative process. Wnt signaling is activated in
response to cardiac injury leading to cardiac remodeling [45].
Chemical inhibition and genetic knockout of GSK3b, a signaling
mediator in the Wnt/b-catenin pathway has been shown to in-
crease cardiomyocyte cycling by inducing S phase entry [46,47].
One of the proposed mechanisms for postnatal cell cycle arrest is
the down regulation of Wnt signaling. Wnt signaling pathway is,
hence, considered a potential player in stimulating cardiac
regeneration.
Notchpathwayof cell signaling has also been shown tomodulate
cardiomyocyte proliferation and trabculation in the developing
heart [48,49]. One mechanism of Notch signaling is to facilitate the
activity of BMP10 (Bone Morphogenetic Protein e 10), which is
essential for regulating growth and maturation of the heart [48,49].
Experiments have shown that BMP10 knockout mice demonstrate a
dramatic reduction in proliferative activity in cardiomyocytes.
Another mechanism by which Notch signaling affects car-
diomyocyte proliferation is by indirect control of Neuregulin
expression [49]. Neuregulin induces cardiomyocyte proliferation as
described in the section of extracellular and paracrine factors. Ven-
tricular amputation injury in zebra ﬁsh activates the Notch pathway
in the regenerative response speciﬁcally in the endocardium and
epicardium [50]. Unexpectedly, however, it was shown that hyper-
activation of Notch signaling also suppresses cardiomyocyte prolif-
eration [50]. This would mean that cardiomyocyte proliferative
renewal could be sensitive to disturbance in Notch signaling [50].
Hippo signaling pathway has generated interest in recent years
as it regulates heart size by inhibiting cellular proliferation. This
effect of the Hippo signaling is mediated by inhibition of a subset of
Wnt target genes [51]. In adult cardiomyocyte, it was also shown
that cardiomyocytes re-enter the cell cycle upon Hippo pathway
disruption and proceed to cytokinesis and regeneration of the
myocardium. Hippo-deﬁcient cardiomyocytes also demonstrated
reduced scar size, increased survival and proliferation after ven-
tricular apical resection injury [52]. Further studies have shown
that neonatal and adult mouse cardiomyocyte cycling was
enhanced after manipulating various regulators of the Hippo
pathway [52e54]. One of the mechanisms of Hippo signaling in-
volves phosphorylation of the transcriptional co-activator YAP (yes-
associated protein). A conditional deletion of YAP-1 during heart
development results in impaired myocyte proliferation; hence its
importance in proper fetal heart growth [55].
Overexpression of a constitutively active mutant YAP was
shown to enhance myocyte proliferation and improve heart func-
tion after MI in adult mice [53]. Also, adeno-associated
virusemediated delivery of human YAP in mice post-MI produced
beneﬁcial results [56].
Hippo-YAP pathway is linked to the PI3K-AKT signaling
pathway. It is also through this route that Hippo-YAP causes car-
diomyocyte proliferation [57]. These results clearly show that
Hippo off and on signaling is a viable target for inducing adult
cardiomyocyte proliferation.
Jak/Stat signaling pathway is a developmental pathway closely
linked to cardiac regeneration. Inhibition of this signaling in zebra
ﬁsh has led to reduced cardiomyocyte proliferation and increased
scarring after cardiac injury [58]. Experimental myocarditis model
in mice demonstrated that recovery from myocarditis-induced
damage was due to proliferation of pre-existing cardiomyocytes
by cell cycle reentry through STAT3. This was shown by immuno-
staining with cell cycle markers Ki-67 and Aurora B. The car-
diomyocyte nuclei were counted to determine that therewas a high
proportion of mononucleated cardiomyocytes that have entered
the cell cycle and underwent cell division. Cell fate mapping anal-
ysis further substantiated the claim that STAT3 is not only a pro-
tective factor but also as a proliferative factor in adult mammalian
cardiomyocytes [59].
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p38 mitogen-activated protein kinase is a signaling molecule
that induces cell cycle exit and differentiation of cardiomyocytes
[60]. It is a negative regulator of mammalian cardiomyocyte divi-
sion both in vitro and in vivo [61]. Expression of cyclin A2, cdc2a,
and cyclin B is increased by inhibition of p38. Its inhibition and
growth factor stimulation act synergistically to induce genes
involved in cardiomyocyte proliferation and regeneration,
including Ki67, cdc2, and cyclin A, and the cell cycle inhibitor p27. It
also leads to phosphorylation of Rb, a key cell cycle regulator [61].
P38 activity, thus not only regulates cell cycle factors as shown
above but also regulates neonatal and adult cardiomyocyte karyo-
kinesis and cytokinesis [61].
4. Paracrine factors in inducing adult cardiomyocyte
proliferation
Extracellular and paracrine factors can stimulate receptors on
cardiomyocytes and induce proliferation through intracellular
signaling pathways.
Neuregulin-1 is an agonist of ErbB1-4 which are the tyrosine ki-
nases receptor of the epidermal growth factor receptor family [62].
This binding to the cardiomyocyte cell-surface receptor increases its
kinase activity leading to stimulation of intracellular PI3-kinase
signal transduction pathway [63]. Neuregulin-1- induces cell cycle
proliferationproceeding to cell division in adult cardiomyocytes [63].
It induces differentiated cardiomyocytes to reenter the cell cycle
from S phase and undergo both karyokinesis and cytokinesis leading
to cardiomyocyte proliferation [63,64]. This effectwas also seen after
myocardial infarction leading to cardiac repair and improved heart
function. Thus, Neuregulin-1/ErbB4 and Neuregulin-1/ErbB2 axes
can be seen as a new molecular strategy for heart regeneration.
However targeting Neuregulin-Erb pathway may not be straight-
forward as persistent activation has been shown to ultimately lead to
cardiac hyperplasia and heart failure in animal models [27,65,66].
Insulin like growth factor-1 (IGF-1) is a mitogen that binds to IGF-
1 receptor to initiate a nexus of intracellular signaling. IGF-1 links
the Wnt, Hippo and PI3K pathways for coordinating cardiac
chamber morphogenesis and embryonic heart size [54,67]. In
transgenic mice, cardiac over expression of IGF-1 stimulated car-
diac proliferation and subsequently caused an increase in cardiac
weight. Constitutive overexpression of IGF-1 has been seen to
prevent cell death after myocardial infarction and limit ventricular
dilatation [68,69].
Fibroblast growth factor-1 (FGF-1) belongs to a group of
secreted signaling proteins as paracrine or endocrine signals in
development, health, and disease in major organs [70]. Paracrine
FGFs exert biological activities by binding to cell surface FGF re-
ceptors (FGFR) and heparan sulfate as a co-factor. The FGF-FGFR-
heparan sulfate complex leads to the activation of intracellular
signaling pathways including the RAS-MAPK, PI3K-AKT, phospho-
lipase Cg (PLCg), and STAT pathways [71e73]. Stimulation of adult
cardiomyocytes with FGF-1 together with p38 inhibition act
sequentially to promote induction of DNA synthesis as well as G2/M
transition in cardiomyocytes [61]. In vivo, post MI p38 inhibition
facilitates FGF1-mediated cardiomyocyte mitosis within the infarct
and at the border zone leading to preserved myocardial wall
thickness, reduced scaring, and improved function [74]. It has also
been shown that FGFR-1interacts with Fn14 (TNF receptor super-
family member ﬁbroblast growth factor-inducible molecule 14) to
enable cardiomyocyte cell cycle reentry [75].
Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the
Interleukin-6 family. It is involved in dedifferentiation [76], cell
proliferation and inﬂammatory processes [77]. OSM induces car-
diomyocyte dedifferentiation and activation of fetal genes, expres-
sion of progenitor cell markers and enables cell-cycle progression
[78]. These effects of OSM are mediated by the Ras/Raf/MEK/Erk
signaling cascade. OSM seems to be beneﬁcial after acutemyocardial
infarction but prolonged dedifferentiation leads to reduction in
contractile force of the heart and ultimately heart failure [78].
Agrin. Cell cycle reentry needs extracellular matrix proteins
(ECM) for a coordinated proliferation-differentiation of adult car-
diomyocytes [79,80]. In vitro administration of ECM fragments from
post natal day 1 (P1) but not day 7 (P7), promoted an increase in cell
cycle activity in P1 and P7 isolated cardiomyocytes and co-treatment
with a broadmatrix metalloproteinase inhibitor resulted in reduced
cardiomyocyte proliferation induced earlier [80]. It was seen that
Agrin, a large extracellular hepran sulfate proteoglycan was down-
regulated between P1 and P7 aswell as in the adult heart. Agrin dose
dependently increased P1 and P7 cardiomyocyte proliferation, evi-
denced by immunoﬂuorescence staining formarkers of proliferation
Ki67, phospho-histone H3 and aurora kinase B. Intramyocardial in-
jection of Agrin after experimental myocardial infarction in juvenile
and adult hearts also induced cardiomyocyte cell-cycle re-entry in
the region adjacent to the infarcted myocardium, reduced scar size
and improved cardiac function. Mechanistically, Agrin is shown to
destabilize the dystrophin-glycoprotein complex, promoting
myoﬁbril disassembly with activation of downstream signaling
molecules Yap and ERK [80].
Periostin, a secreted extracellular matrix protein [81] is
expressed in the developing heart, but not in healthy adult ven-
tricular myocardium [82]. It is re-expressed in adult ventricular
myocardium following injury [83]. Recombinant periostin has
shown to induce reentry of differentiated mononucleated car-
diomyocytes into the cell cycle [84]. Periostin induced full mitotic
cycle in differentiated cardiomyocytes as evidenced by an increase
in cardiomyocyte DNA synthesis, aurora B kinase detection and
Brd-U positive nuclei in 100% of cardiomyocyte cytokinesis [84].
Periostin-induced cardiomyocyte cell-cycle reentry was through
the PI3K pathway and required various integrins. Myocardial de-
livery of periostin improved ventricular remodeling and function
after myocardial infarction. It reduced ﬁbrosis, infarct size and
increased angiogenesis [84]. The above ﬁndings were challenged by
reports of no role of periostin in cardiomyocyte proliferation and
regeneration in the adult heart [85,86]. However, recently Chen
et al [87] has provided comprehensive evidence that periostin is
required for cardiomyocyte proliferation, angiogenesis and regen-
eration of the neonatal heart post-MI. They examined the impact of
genetic loss-of-function in neonatal mice following MI and showed
that PI3K/Akt/GSK3b signaling mediates the pro-regenerative ac-
tions of periostin [87].
5. Transcriptional factors mediation of cardiomyocyte
proliferative response
Cell cycle regulators are also controlled by various transcription
factors. The role of different transcriptional factors in cell cycle
mediation are summarized in Table 1.
E2F are a family of transcription factors that form a complex
network with the pocket protein in the cell cycle to regulate car-
diomyocyte proliferation and differentiation [88]. E2F-1 stimulates
DNA synthesis in post mitotic rat ventricular myocytes. It leads to
accumulation of myocytes in G2/M phase of the cell cycle over-
riding the G1/S checkpoint followed by an increase in the rate of
apoptosis and mortality [89,90] .Overexpression of E2F-2, however,
is shown to stimulate cardiomyocyte cycling. Targeted expression
of E2F-2 in mice showed a signiﬁcant increase in the number of
cardiomyocytes within S-phase, along with a signiﬁcant increase in
phosphorylated histon-H3 and Aurora-kinase positive car-
diomyocytes demonstrating that the cardiomyocytes completed
the entire cell cycle including mitosis and cytokinesis [91]. Table 1
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shows the genomic response of E2F-2 on the up regulation of both
cyclin A and E.
It has also been shown that knocking down the E2F regulatory
pocket proteins, Rb and p107 caused an increase in the car-
diomyocyte cycling [92,93]. Since hypophosphorylated Rb binds to
E2F complexes, its phosphorylation is carried out by CDK2 and
CDK4, which in turn, releases the E2F complexes. E2F complexes
activate transcription triggering expression of genes needed for
DNA synthesis and regulation of cell cycle. Rb and p130 maintain
the post mitotic state of adult cardiomyocytes. They do so by
directing heterochromatin formation and silencing a subset of E2F-
dependant pro-proliferation G2/M and cytokinesis genes. It has
been shown that cardiomyocyte cell cycle re-entry can be achieved
by reversal of this silencing mechanism [92].
Meis1 is a transcription factor and a key regulator of cell cycle
arrest. Meis1 plays an important role in embryonic cardiomyocyte
development [94]. It maintains high levels of the cyclin-dependent
kinase inhibitors p15, p16 and p21 postnatally by directly regu-
lating these genes [95]. Meis1-binding sequences have been found
in the promoter regions of genes. Recent studies have shown that
deleting Meis1 in cardiomyocytes extended the cardiomyocyte
proliferative window postnatally from 7 to 14 days. It induces cell
cycle reentry and induction of proliferation in adult cardiomyocytes
without reducing heart function or inducing cardiomyocyte hy-
pertrophy. Graphical representation of Meis-1in Table 1 shows its
genomic effects on p15, 16 and 21, which in turn switches off the
CDK6, 4 and 2 subsequently decreasing cyclin D and E. Evidence
suggests therefore, that the limited postnatal cardiac regeneration
in mammals is the result of a Meis1-imposed limit on the division
and proliferation of cardiomyocytes [24].
Tbx20 is a transcription factor essential for cardiomyocyte pro-
liferation during development. Its absence causes embryonic death
at mid-gestation [96]. Induced knockout of Tbx20 in adult car-
diomyocytes also causes severe cardiomyopathy and death [97].
Table 1
Transcription factors and their role in cardiomyocyte cell cycle regulation.
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This shows that Tbx20 is required for fetal as well as adult car-
diomyocyte homeostasis [98]. Tbx20 binds to p21, Meis1, and Btg2
gene sequences and represses their expression [98] which in turn
contributes to Tbx20-induced cardiomyocyte proliferation. This is
shown by increase in the total number of cardiomyocytes and
increased expression of mitotic markers with corresponding
changes in cell-cycle regulatory genes. Over expression of Tbx20
causes adult cardiomyocytes to have fetal-like characteristics.
These include 1. Small mononucleated cardiomyocytes; 2. Up
regulation of fetal contractile protein expression of ssTNI and bMHC
and 3. Induction of multiple proliferative signaling pathways like
PI3K/Akt, Hippo/Yap and BMP/Smad1/5/8 signaling pathways [98].
The cardiomyocyte proliferation is seen without hypertrophy or
ﬁbrosis in normal as well as injured hearts [98].
Tbx20, therefore, possesses a dual genomic switch as shown in
Table 1. On one hand, the expression of cyclin D, E and IGF-1 is
switched on to drive the cardiomyocyte cycle. On the other hand it
switches off the genomic expression of Meis-1, btg-2 and p21 to
induce proliferation in adult cardiomyocytes.
GATA-4 is a zinc ﬁnger transcription factor that plays a key role
during heart development. It regulates speciﬁc genes that mediate
the development of the embryonic and neonatal heart [99,100]. In
neonatal heart, ablation of Gata4 in the cardiomyocytes decreases
cardiomyocytes proliferation following apical resection and cry-
oinjury [101]. GATA4 is also crucial in adulthood where it regulates
cardiomyocyte viability, cardiac hypertrophy, and ﬁbrosis [102,103].
Mechanistic studies have shown that GATA4 exerts its effects via
regulation of Fgf16 (ﬁbroblast growth factor 16) [101]. It is a
cardiac-speciﬁc member of the Fibroblast Growth Factor family of
signaling proteins essential for cell proliferation and tissue regen-
eration [72]. In the fetus, Fgf16 is required for cardiomyocyte
replication during development [104]. Its expression is increased in
the post natal period and throughout adulthood. It is stored in the
extracellular matrix to help maintain cardiac homeostasis by
upregulating the genes associated with cell proliferation and pro-
tecting the heart from injury [101,105]. Thus GATA4/Fgf16 axis is an
important player in regulation of heart regeneration by switching
on cyclin A2 and CDK4 as depicted in Table 1.
Hypoxia-inducible factor (HIF)-1 a is a transcription factor com-
plex that regulates the cellular response to hypoxia [106]. HIF is a
heterodimeric protein made up of the constitutive expressed HIF-
1b and the oxygen sensitive hypoxia-inducible HIF-1a [107]. Cells
continuously synthesize and degrade HIF-1a protein in normoxic
conditions as von HippeleLindau tumor suppressor protein (pVHL)
interacts with the a-subunit to target for proteolysis by the
ubiquitineproteasome pathway [108,109]. HIF-a protein escapes
proteasomal degradation in hypoxic conditions, stabilizes, trans-
locates to the nucleus and dimerizes with HIF-1b. This complex
then binds to the HRE (Hyoxia responsive elements) sequences of
target genes [110] and results in their transcription. Regarding the
role of HIF-1 a in cardiomyocyte proliferation, studies have shown
that after ventricular resection, the zebra ﬁsh heart regeneration
was mediated by HIF-1 a as a crucial player in hypoxic response to
injury [111]. Recently it was shown that during development, there
is a distinct subset of cardiomyocytes that are hypoxic due to their
locationwithin the non-vascularized regions of themid-gestational
fetal heart. This hypoxic environment promoted fetal car-
diomyocyte proliferation as part of the cell stress pathways regu-
lated by HIF-1a [112]. Genetic studies however, have shown that
HIF-1 a induce cell cycle arrest by displacing the transcription
factor Myc binding from the promoter of p21 which is a CDK in-
hibitor and controls the cell cycle checkpoint as shown in Table 1.
This action of HIF-1 a is independent of its DNA binding or tran-
scriptional activity. HIF-1a, therefore, has at least two mechanisms
for regulating gene expression: its C-terminal transactivation of
genes through its HRE, and via its N-terminal counteraction of Myc
Fig. 2. Molecular switch model. It shows how the cell cycle is regulated through on- and off switch mechanisms through interaction of transcription factors, signaling pathways,
paracrine factors and epigenetic regulators upon cell cycle checkpoint proteins as elucidated in the text.
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activity. This indicates a divergent role for HIF-1a in cardiac pro-
liferation and development [88,113].
6. The ‘molecular switch’ model
Endogenous cardiac repair by stimulating adult cardiomyocytes
proliferation is an exciting possibility that is showing promise in
the light of animal experiments. However, there are fundamental
questions that are yet to be answered before therapeutic endoge-
nous cardiac repair becomes a reality in humans. As we know that
cell cycle reentry of adult cardiomyocytes can have different results.
This can be limited to the S phase, the phase of karyokinesis or it
can progress all the way to cytokinesis. Recent studies suggest that
only one third of the cardiomyocytes that enter the cell cycle
progress through mitosis and enter cell divisions [88,114]. This
means that the proliferative potential is limited to only a subset of
cardiomyocytes. What might be the characteristics of these adult
cardiomyocytes that enable them to divide? Is it limited to being
mononuclear and diploid myocytes or are there other morpho-
logical and functional features?
For cell division, the cardiomyocytes need to rapidly and accu-
rately disassemble and reassemble cytoskeletal and nuclear struc-
tures in addition to cellecell and cell matrix attachments. A recent
study used time-lapse video microscopy to show myocyte prolif-
eration in adult mouse myocytes cocultured with neonatal rat
ventricular myocytes. Adult cardiomyocytes showed a continuous
process of dedifferentiation with sarcomere disassembly and in-
duction of cell cycle markers, proliferation and redifferentiation
with reorganization of sarcomere and restoration of contractility
[115].
Epigenetic regulation of cardiomyocyte proliferation is a new
area that is being explored recently. Post-translational modiﬁcation
of histone proteins such as DNA methylation, de-acetylation,
phosphorylation and microRNA mediated gene regulation have
been found to inﬂuence expression of cell cycle factors in the adult
heart [116]. Cardiac speciﬁc transcriptional factors such as GATA4,
Tbx5 and cell cycle regulators Rb/p130 have been shown to form
complexes with epigenetic modifying proteins and these complex
lead tomodiﬁcations of histones at promoter regions of cardiac and
cell cycle genes which determines the adult cardiomyocyte
phenotype [116].
Reviewing studies of the various transcription factors, signaling
proteins, along with physical interactions that play a role in adult
cardiomyocyte proliferation we have modeled a molecular switch
that transforms the post mitotic cell into an actively dividing cell
(Fig. 2). Signals triggered by injury may activate the right combi-
nation of signaling molecules and transcription factors that can
‘switch on’ the proliferation signals leading to myocardial regen-
eration. What might be the right combination is yet to be deﬁned.
Another important question is how to control the “off” switch of
cardiac proliferation once the “on” switch is triggered?Much needs
to be done in understanding the basic mechanisms that regulate
the molecular switch of adult cardiomyocyte division and prolif-
eration before therapeutic regenerative approaches are applicable.
Cardiomyocyte proliferation is an essential part of the heart
regeneration story but it cannot be emphasized enough that
renewal of a piece of myocardium needs contributions from car-
diomyocytes, endothelial cells, smooth muscle cells, ﬁbroblast,
pacemaker cells, conducting and Purkinje cells to bring the
orchestration of rhythmically contracting and relaxing heart [117].
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